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Purpose
Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma
(nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of tem-
sirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
Materials and Methods
From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC
patients, who were treated with temsirolimus according to the standard protocol, were col-
lected. The primary end-point was progression-free survival (PFS). Secondary end points
were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results
Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retro-
spective groups, were enrolled; 24 patients (54%) were papillary type, and other histology
subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translo-
cation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6
months, respectively. ORR was 11% and disease control rate was 83%. Patients with prior
nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to
0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favor-
able/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7
months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2
months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).  
Conclusion
Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable
or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable 
adverse events.
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Introduction
Renal cell cancer (RCC) is a heterogeneous disease that is
diversified by its pathologic subtypes, genetic alterations,
and clinical outcomes [1,2]. It is mainly divided into two
pathological subtypes based on pathologic phenotype, clear
cell, and non-clear cell types, with the latter defined as less
than 50% of clear cells [3].
The incidence of non-clear cell RCC (nccRCC) is no more
than 8%-20% [4]. Its rarity and poor prognosis have made it
difficult to determine the best treatment option. In recent
years, tyrosine kinase inhibitors (TKIs) targeting vascular 
endothelial growth factor receptor (VEGFR) pathways, such
as sunitinib [5,6] and sorafenib [7,8], and mammalian target
of rapamycin (mTOR) inhibitors, such as temsirolimus [9,10]
and everolimus [11,12], have been developed for the treat-
ment of advanced/metastatic RCC [13]. Temsirolimus is an
inhibitor of mTOR kinase, which is part of a signaling path-
way associated with growth and proliferation of cells. Dis-
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ruption of mTOR thereby results in suppression of cell cycle
and angiogenesis [14,15].
Global Advanced Renal Cell Cancer (ARCC) phase 3 trial
showed that 40 nccRCC treatment-naïve patients with poor
prognosis, who received temsirolimus, had a median pro-
gression-free survival (mPFS) of 3.8 months and median
overall survival (mOS) of 10.9 months. However, there is no
data on the efficacy of temsirolimus in less extensive, rela-
tively favorable and intermediate prognosis in nccRCC, 
especially in Asian patients.
The aim of this retrospective, multicenter prospective
study is to investigate the efficacy and tolerability of tem-
sirolimus in treatment-naïve Asian patients with metasta-
tic/recurrent nccRCC.
Materials and Methods
1. Study design
This is a combined analysis of 44 patients from the pro-
spective study and retrospectively collected cases. Data of 10
patients from prospective group were collected from five
medical centers that participated in a non-randomized, phase
II, multicenter prospective trial from May 2011 to February
2015. The study was closed prematurely when temsirolimus
was approved by Ministry of Food and Drug Safety and 
reimbursed in South Korea on June 1, 2011, as the standard
first-line treatment for metastatic/recurrent nccRCC. Then,
34 patients who received temsirolimus using the same pro-
tocol of the prospective study at Yonsei Cancer Center from
January 2008 to July 2017 were retrospectively analyzed in
conjunction with the prospective group.
The primary end-point was progression-free survival
(PFS). Secondary end points were overall survival (OS), 
objective response rate (ORR), disease control rate, safety,
and tolerability of temsirolimus.
2. Patient selection
Inclusion criteria included histologically confirmed nccRCC
(papillary, chromophobe, collecting duct, Xp11.2 transloca-
tion, others as unclassified) defined as metastatic and recur-
rent stage IV with a measurable or evaluable lesion by
Response Evaluation Criteria in Solid Tumors (RECIST);
Eastern Cooperative Oncology Group (ECOG) performance
status 0-2; and adequate liver, renal, bone marrow functions.
Before enrollment, pathology including questionable cases
was reviewed by a pathologist who specialized in urology
pathology at Yonsei Cancer Center. Patients were ineligible
if they had received any prior chemotherapy treatment for
renal cell carcinoma.
3. Treatment and evaluation
The patients received 25 mg of temsirolimus administered
in a weekly 30-minute intravenous infusion, and four weekly
infusions were considered as one cycle. Treatment continued
until unacceptable toxicity, disease progression, death, or 
patient’s withdrawal of consent. Doses were interrupted
based on relevant hematologic and non-hematologic effects,
according to National Cancer Center Institute-Common Ter-
minology Criteria of Adverse Events (NCI-CTCAE v.4.0).
Dose was not reduced if adverse events (AEs) could be man-
aged with conservative care. Temsirolimus was withheld for
a maximum of 3 weeks for grade 3 or 4 AEs, and restarted at
a reduced dose after recovery to grade 2 or lower. Dose was
reduced to 20 mg/m2 weekly, and there was no reduction of
more than 15 mg/m2 weekly.
To evaluate tumor size, computed tomography was repea-
ted every two cycles (4 weeks considered as one cycle) with
RECIST criteria 1.1. In patients who were enrolled in the
prospective study, chest computed tomography evaluation
was performed at the time of baseline and 8 weeks after treat-
ment to evaluate pulmonary toxicity, such as noninfectious
pneumonitis. Both Memorial Sloan Kettering Cancer Center
(MSKCC) and ARCC risk groups, with the latter including
the criteria of metastatic lesions in  2 organs, were used to
determine prognosis.
4. Statistics
Descriptive analysis was used to describe baseline charac-
teristics and AEs. Survival curves were calculated using the
Kaplan-Meier method. All statistical analyses were per-
formed using SPSS statistical software ver. 25 (IBM Corp.,
Armonk, NY), SAS software ver. 9.4 (SAS Inc., Cary, NC),
and R software ver. 3.5.0, (R Foundation for Statistical Com-
puting, Vienna, Austria).
In prospective study, the following assumptions were
made in the estimation of required sample size for primary
end-point, PFS. The null hypothesis was that PFS (H0) is 3.1
months. H0 was estimated from the previous trial of inter-
feron  with PFS of 3.1 months. If temsirolimus had PFS of
less than 3.1 months, trial would not proceed. The alternative
hypothesis (H1) was that PFS will be 5.5 months for treat-
ment-naïve patients. This was based on the previous study
of treatment-naïve and previously treated RCC patients who
had similar PFS of 5.5 months and 6.3 months, respectively
[13]. Sample size was calculated using Simon’s optimal two-
stage design. With one-sided significance level of 0.05, a
power of 0.9 to reject the null hypothesis, and a 10% drop-
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out rate, the final sample size was calculated to be 30 pati-
ents.
5. Ethical statement
This study was conducted in accordance with the Declara-
tion of Helsinki, and was consistent with Good Clinical Prac-
tice. The institutional review board (IRB) of six centers
approved the study protocol (IRB No. 4-2017-0727), and the
study was registered in Korean Cancer Study Group (KCSG)
(No: GU11-03). All patients from the retrospective cases were
exempted from the written consent, according to the study
protocol approved by IRB of Severance Hospital (IRB No. 
4-2017-1056).
Results
1. Patient characteristics
In this study, a total of 44 patients were enrolled; 10 from
prospective group and 34 from retrospective group. Table 1
lists the baseline characteristics of patients. The median age
was 52 years (range, 17 to 84 years), and 32 patients (73%)
were male. Twenty-four patients (54%) were papillary type
renal cell carcinoma (pRCC), and among them, 19 patients
were categorized as type 2 pRCC (two patients had type 1
pRCC, three patients were not sub-classified). Other histol-
ogy subtypes included 11 chromophobes (25%), two collect-
Table 1. Baseline characteristics 
(Continued)
Variable No. (%) (n=44)
Age, median (range) 52 (17-84)
Sex
Male 32 (73)
Female 12 (23)
Histology 
Papillary 24 (54)
Chromophobe 11 (25)
Collecting duct 2 (5)
Xp11.2 translocation 1 (2)
Others 6 (14)
Sarcomatoid component
Yes 13 (29)
No 31 (71)
Initial stage of diagnosis 
I 5 (11)
II 3 (7)
III 6 (14)
IV 30 (68)
Previous nephrectomy 
Curative 19 (43)
Cytoreductive 11 (25)
Previous radiotherapy 
Yes 2 (5)
No 42 (95)
No. of metastatic sites
0 1 (2)
1 26 (59)
2 11 (25)
 3 6 (14)
Sites of metastatic disease 
Lung 17 (39)
Lymph node 18 (41)
Bone 12 (27)
Liver 9 (21)
ARCC parameter 
Low hemoglobina) 26 (59)
Elevated calcium > 10 mg/dL 2 (5)
(> 2.5 mmol/L)
Elevated LDH 7 (16)
Performance status < 80% 3 (7)
Time from diagnosis to 32 (73)
systemic treatment < 1 yr
No. of metastatic sites  2 17 (39)
ECOG
0 33 (75)
1 8 (18)
2 3 (7)
Table 1. Continued
ARCC, Advanced Renal Cell Cancer; LDH, lactate dehy-
drogenase; ECOG, Eastern Cooperative Oncology Group;
MSKCC, Memorial Sloan Kettering Cancer Center. a)Men
< 13.5g/dL, women < 12.0 mg/dL.
Variable No. (%) (n=44)
ARCC
Favorable (0) 5 (11)
Intermediate (1-2) 24 (55)
Poor ( 3) 15 (34)
MSKCC
Favorable (0) 6 (14)
Intermediate (1-2) 34 (77)
Poor ( 3) 4 (9)
2nd-line treatment 
Yes 11 (25)
No 33 (75)
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ing ducts (5%), one Xp11.2 translocation (2%), and six others
(14%). Thirteen patients (71%) had sarcomatoid components.
Thirty patients were initially diagnosed as stage IV, and
two-thirds of the patients had nephrectomy, 19 for curative
and 11 for cytoreductive purposes. Except for one patient
who had local relapse, 43 patients had one or more metastatic
sites such as lung, lymph node, bone, and liver metastasis.
Most of the patients (80%) were treated within a year after
initial diagnosis. When patients were categorized by risk
groups, 15 patients were classified as poor-risk according to
ARCC criteria and four patients by MSKCC criteria.
2. Efficacy
Out of 44 patients, 35 patients were evaluable. Three pati-
ents (9%) showed complete response, one patient (3%)
showed partial response, and 25 patients (70%) showed sta-
ble disease, resulting in overall response rate (ORR) of 11%
and disease control rate (DCR) of 83% (Table 2). The duration
of response was at least 15 months (median, 29.2 months;
95% confidence interval [CI], 15.60 to 66.40) for all four res-
pondents, and responses were maintained at the time of data
analysis. At the time of analysis, 34 patients showed disease
progression and 26 patients died. The cause of death was dis-
ease progression for 24 patients. The median PFS was 7.6
months (95% CI, 5.0 to 10.2) and median OS was 17.6 months
(95% CI, 0 to 39.1) (Fig. 1).
The patients were further subdivided into pathological
subtypes, sarcomatoid features, and prognosis groups. No
significant difference in PFS or OS was observed in histolog-
ical subtypes (Figs. 2 and 3). There was also no correlation
between PFS and sarcomatoid features. However, patients
without sarcomatoid features had longer OS (33.7 months)
compared to patients with sarcomatoid features (9.2 months)
(p=0.025). Poor prognosis group defined by ARCC criteria
had a trend for shorter PFS and OS. PFS of poor prognostic
group was 4.7 months compared to 19.3 months of favor-
able/intermediate group (p=0.005). OS was 9.2 months (95%
CI, 1.23 to 6.56) in poor prognostic group and 43.1 months in
favorable/intermediate group (p=0.015).
3. Safety and tolerability
Table 3 shows AEs. During treatment, 37 patients (84%)
experienced one or more AEs. Thirty patients (68%) had
Table 2. Summary of response
CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease. 
No. of evaluable
patients (%) (n=35)
Best response
CR 3 (9)
PR 1 (3)
SD 25 (70)
PD 6 (18)
Response rate (CR+PR) 4 (11)
Disease control rate (CR+PR+SD) 29 (83)
Duration of treatment, median (range, wk) 11 (1-209)
Patients with  1 dose reduction-number 13 (30)
Patients with  1 dose delay-number 15 (34)
Fig. 1.  Efficacy of temsirolimus in non-clear cell renal cell carcinoma. (A) Progression-free survival (PFS). (B) Overall survival
(OS). CI, confidence interval.
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symptoms/signs, and 27 patients (61%) had lab/imaging 
abnormalities that were related to temsirolimus. The most
common AEs were stomatitis (34%), fatigue (27%), anorexia
(18%), and rash (16%). The most frequent laboratory and 
imaging abnormalities were hyperglycemia (23%), hyperc-
holesterolemia (18%), hypertriglyceridemia (16%), and non-
infectious pneumonitis (16%). Particularly, AEs of grade > 3
were noted in stomatitis (9%), hypertriglyceridemia (11%),
hyperglycemia (9%), and noninfectious pneumonitis (7%).
Twenty-six patients (59%) who experienced AEs of grade 3
had dose reduction or delayed treatment. A total of four pati-
ents (9%) discontinued treatment due to stomatitis (one pati-
ent), noninfectious pneumonitis (two patients), and crea-
tinine elevation (one patient). There was no treatment-related
mortality.
The median duration of treatment was 11 weeks (ranging
from 1 to 209). Thirteen patients (30%) had more than one
dose reduction, and 15 patients (34%) had more than one
dose delays.
B
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Fig. 2.  Kaplan-Meier curves of progression-free survival (PFS) according to subgroups. (A) With or without sarcomatoid
features. (B) Papillary, chromophobe, others. (C) Prognostic group by Advanced Renal Cell Cancer criteria. HR, hazard ratio;
CI, confidence interval.
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4. Prognostic factors affecting survival
In univariate analysis, factors such as previous nephrec-
tomy (p < 0.001) and favorable/intermediate prognosis 
defined by ARCC and MSKCC (p=0.005 and p=0.024, respec-
tively) were associated with improved PFS (Table 4). Factors
that were associated with poor OS were poor ECOG per-
formance status (p=0.009), presence of sarcomatoid compo-
nent (p=0.025), absence of previous nephrectomy (p < 0.001),
and poor prognosis defined by ARCC and MSKCC (p=0.015
and p=0.004, respectively).
In multivariate Cox regression analysis, prognostic factor
defined by ARCC was selected because it was the criteria
used in the Global ARCC trial which showed that nccRCC
with poor prognosis benefit from temsirolimus. MSKCC was
disregarded in order to avoid interaction between the two
parameters. Patients with prior nephrectomy tended to have
better PFS (HR, 0.16; 95% CI, 0.06 to 0.42; p < 0.001). Sarco-
matoid component (HR, 3.07; 95% CI, 1.12 to 8.39; p=0.029)
and previous nephrectomy (HR, 0.15; 95% CI, 0.05 to 0.45; 
Fig. 3.  Kaplan-Meier curves of overall survival (OS) according to subgroups. (A) With or without sarcomatoid features. (B)
Papillary, chromophobe, others. (C) Prognostic group by Advanced Renal Cell Cancer criteria. HR, hazard ratio; CI, confi-
dence interval.
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p < 0.001) were significantly associated with OS.
Notably, second-line treatment did not affect the OS. Only
11 patients (25%) received second-line chemotherapy which
included eight patients who received TKIs such as pazo-
panib, sunitinib, axitinib, and three patients who received
chemotherapy (Table 1). Therefore, our results suggested
that temsirolimus as first-line of treatment was crucial in 
determining the OS of nccRCC.
Discussion
This study included both prospective and retrospective
data of temsirolimus as first-line treatment in treatment-
naïve Asian patients with metastatic/recurrent nccRCC. All
of the 34 patients from retrospective group were treated with
the same standard protocol from the prospective study at
Yonsei Cancer Center. Since the majority of data was col-
lected from a single center with consistent protocol, hetero-
geneity of data was minimized. Our results showed that
patients had ORR of 11%, DCR 83%, mPFS of 7.6 months,
and mOS of 17.6 months. When patients were further cate-
gorized by favorable/intermediate and poor prognosis
group was defined by Hudes et al. [9] the mPFS and mOS for
poor prognosis group were 4.7 and 9.2 months, respectively.
These results are comparable to those of pivotal temsirolimus
studies, particularly the Global ARCC trial.
Global ARCC trial, which was a randomized phase 3 study
of temsirolimus versus interferon  or both for clear cell (586
patients) and nccRCC (40 patients), showed that patients 
defined as poor prognosis who were administered with tem-
sirolimus had mPFS of 3.8 months and mOS of 10.9 months.
Thus, temsirolimus has been used as standard treatment for
nccRCC with poor prognosis. In our study, one-third of the
patients were classified as poor-risk, which may explain why
our study had longer mPFS and mOS. Therefore, temsiro-
No. of patients (%)
All grades Grade  3 All grades Grade  3 All grades Grade  3
Symptoms and signs (n=30, 68%)
Anorexia 5 (15) 2 (6) 3 (30) - 8 (18) 2 (5)
Nausea/Vomiting 2 (6) 1 (3) 1 (10) - 3 (7) 1 (2)
Fatigue 8 (24) 2 (6) 4 (40) 3 (30) 12 (27) 5 (11)
Stomatitis 10 (30) 1 (3) 5 (50) 3 (30) 15 (34) 4 (9)
Hand-foot syndrome 3 (9) - - - 3 (7) -
Rash 5 (15) - 2 (20) 1 (10) 7 (16) 1 (2)
Pruritus 2 (6) - 3 (30) - 5 (11) -
Headache 1 (3) - 1 (10) - 2 (5) -
Alopecia 1 (3) - - - 1 (2) -
Edema 1 (3) - 2 (20) - 3 (7) -
Scrotal swelling - - 1 (10) - 1 (2) -
Leg pain - - 2 (20) - 2 (5) -
URI 3 (9) - 2 (20) - 5 (11) -
Diarrhea - - 1 (10) - 1 (2) -
Insomnia - - 1 (10) - 1 (2) -
Lab and imaging abnormalities (n=27, 61%)
Anemia 3 (9) - - - 1 (2) -
Leukopenia 1 (3) - 2 (20) 1 (10) 3 (7) -
Thrombocytopenia - - 1 (10) - 1 (2) -
Increased AST/ALT 2 (6) - 1 (10) - 3 (7) -
Increased creatinine level 1 (3) - 1 (10) - 2 (5) -
Hyperglycemia 10 (30) 4 (12) - - 10 (23) 4 (9)
Hypercholesterolemia 6 (18) - 2 (20) - 8 (18) -
Hypertriglyceridemia 5 (15) 4 (12) 2 (20) 1 (10) 7 (16) 5 (11)
Noninfectious pneumonitis 7 (21) 1 (3) - - 7 (16) 1 (2)
URI, upper respiratory tract infection; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 3. Summary of treatment-related adverse events
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limus may not only benefit poor prognosis group, but also
patients with less extensive metastatic nccRCC. It is impor-
tant to note that there were more patients who were catego-
rized as poor prognostic group by ARCC (15 patients, 34%)
than with MSKCC parameters (four patients, 9%). Since
MSKCC parameters have certain limitations in nccRCC, our
study focused on the prognostic tool defined by Hudes et al.
[9] in Global ARCC trial as reference data. IDMC model 
(International Metastatic Renal Cell Carcinoma) which was
validated in ccRCC VEGFR TKI but not in nccRCC, was also
not considered in this study.
Everolimus, an orally administered mTOR inhibitor in 
nccRCC, was also evaluated in ESPN (Everolimus versus
Sunitinib Prospective Evaluation in Metastatic Non-clear Cell
Renal Cell Carcinoma) [11] and ASPEN [12] studies. ESPN,
a randomized phase 2 study compared the efficacy of evero-
limus and sunitinib in first-line setting in 73 subjects. Suni-
tinib, a vascular endothelial growth factor TKI, had better
mPFS than that of everolimus (6.1 months vs. 4.1 months,
p=0.25) [11]. Similarly, everolimus versus sunitinib for pati-
ents with metastatic nccRCC (ASPEN), a randomized phase
II study of 108 subjects, showed that sunitinib and everoli-
mus had a median PFS of 8.3 months and 5.6 months, respec-
tively [12].
Based on these results, everolimus cannot be recommen-
ded in first-line treatment for nccRCC. On the other hand,
the efficacy of temsirolimus is comparable to that of suni-
tinib. Although temsirolimus has its limitation with weekly
intravenous injection compared to relatively easy oral 
administration of sunitinib, temsirolimus has better manage-
able toxicity profiles compared to sunitinib. In our study,
84% (37 patients) of subjects experienced AEs and 59% (26
patients) had grade 3–related AEs, which were manageable
with dose reductions and dose delays. Only four patients
(9%) discontinued treatment due to AEs.
In ASPEN study, 78% (40 patients) receiving sunitinib 
experienced grade 3 or worse treatment-related AEs. Overall,
53% (27 patients) needed dose reductions and 14% (7 pati-
ents) discontinued treatment due to treatment-related AEs.
AEs related to sunitinib included hypertension, hand-foot
syndrome, nausea/vomiting, diarrhea, and lab abnormalities
such as hypothyroidism, thrombocytopenia, neutropenia,
and elevated liver enzymes [12].
Pazopanib, a VEGFR TKI which was approved in advan-
ced ccRCC, was also investigated in first-line setting in 
nccRCC. First-line pazopanib in nccRCC (PANORAMA)
study which enrolled 37 patients, resulted in mPFS of 15.9
months and mOS of 17.3 months [16]. Pazobanib as second-
line in 29 patients treated had an ORR of 28% with mPFS 16.5
months [17]. Pazobanib’s role in nccRCC may need further
validation. Table 5 summarizes ARCC, ESPN, ASPEN, and
PANORAMA results.
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Although recent advancements have led to the develop-
ment of new targeted drugs such as cabozantinib [18], a
multi-targeted TKI and immune checkpoint inhibitors such
as nivolumab in ccRCC, efficacy results on nccRCC are cur-
rently being investigated. The limitation of this study was
the lack of data collected on parameters, such as lactate 
dehydrogenase, and a part of toxicity profiles in retrospective
data. In addition, low incidence of nccRCC and reimburse-
ment issues were obstacles in collecting larger sample size.
In conclusion, there seem to be several treatment options
for nccRCC. Although temsirolimus and everolimus are both
mTOR inhibitors, everolimus has failed to improve PFS and
OS. Sunitinib and pazopanib are both VEGFR TKIs, but 
pazopanib as first-line nccRCC lacks data. Although 75% (33
patients) did not receive second-line therapy due to fewer
treatments options in South Korea, mOS was 17.6 months,
indicating that the effect of temsirolimus directly translates
to OS. In addition, temsirolimus not only benefits poor-risk
group but also the favorable or intermediate-risk groups, and
has comparable results to those of sunitinib.
Less extensive metastatic nccRCC may benefit from tem-
sirolimus, regardless of histological variations and risk fac-
tors. Additional studies with larger sample size of nccRCC
are needed to validate the results of this study.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Acknowledgments
Prospective part of the study was endorsed by Korean Cancer
Study Group (KCSG, www.kcsg.org) (GU11-03).
This research was partly supported by a grant from the National
R&D Program for Cancer Control, Ministry of Health and Welfare,
Republic of Korea (1720150) and the National Cancer Center, Repub-
lic of Korea (NCC-1810861-1).
Author Details
1Division of Medical Oncology, Department of Internal Medicine,
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,
2Song-Dang Institute for Cancer Research, Yonsei University College
of Medicine, Seoul, 3Division of Medical Oncology, Department of
Internal Medicine, St. Vincent’s Hospital, College of Medicine, The
Catholic University of Korea, Suwon, 4Department of Biostatistics,
Yonsei University College of Medicine, Seoul, 5Department of Inter-
nal Medicine, Chungnam National University, Daejeon, 6Division
of Hematology-Oncology, Department of Internal Medicine, Dong-
nam Institute of Radiological and Medical Sciences, Busan, 7Division
of Hematology-Oncology, Pusan National University, Busan, 8Divi-
sion of Hematology and Medical Oncology, Department of Internal
Medicine, Seoul National University Bundang Hospital, Seongnam,
9Department of Preventive Medicine and Institute of Health Services
Research, Yonsei University College of Medicine, Seoul, 10Division
of Pathology, Yonsei University College of Medicine, Seoul, 11Brain
Korea 21 Project for Medical Sciences, Yonsei University College of
Medicine, Seoul, Korea
Table 5.  Summary of first-line therapy for metastatic nccRCC
nccRCC, non-clear cell renal cell carcinoma; ARCC, Advanced Renal Cell Cancer; ESPN, Everolimus versus Sunitinib
Prospective Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma; ASPEN, Everolimus versus Sunitinib for Patients
with Metastatic Non-clear Cell Renal Cell Carcinoma; PANORAMA, first-line pazopanib in nccRCC; ORR, objective response
rate; PFS, progression-free survival; OS, overall survival.
Study Our study ARCC [9] ESPN [11] ASPEN [12] PANORAMA [16]  
No. of nccRCCs 44 124 73 108 37
Treatment Temsirolimus Temsirolimus (40) Sunitinib (34) vs. Sunitinib (51) vs. Pazopanib
Everolimus (38) Everolimus (57)
Prognosis Any Poor Mostly favorable, Any Any
intermediate
ORR (%) 9 8.6 12 vs. 0 12 vs. 5.0 27
PFS (mo) 7.6 3.8 6.1 vs. 4.1 8.3 vs. 5.6 15.9
OS (mo) 17.6 10.9 16.2 vs. 14.9 31.5 vs. 13.2 17.3
(p=0.18) (p=0.60)
Jii Bum Lee, Temsirolimus in Non-clear Cell Renal Carcinoma
VOLUME 51 NUMBER 4 OCTOBER 2019 1587
1. Lopez-Beltran A, Kirkali Z, Montironi R, Blanca A, Algaba F,
Scarpelli M, et al. Unclassified renal cell carcinoma: a report
of 56 cases. BJU Int. 2012;110:786-93.
2. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM.
The 2016 WHO classification of tumours of the urinary system
and male genital organs-part a: renal, penile, and testicular 
tumours. Eur Urol. 2016;70:93-105.
3. Tsimafeyeu I. Management of non-clear cell renal cell carci-
noma: current approaches. Urol Oncol. 2017;35:5-13.
4. Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A,
Uzzo RG, et al. A review of interventional clinical trials in
renal cell carcinoma: a status report from the ClinicalTrials.gov
WebSite. Clin Genitourin Cancer. 2015;13:142-9.
5. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA,
Oudard S, et al. Final results from the large sunitinib global
expanded-access trial in metastatic renal cell carcinoma. Br J
Cancer. 2015;113:12-9.
6. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, et al.
Treatment outcomes of sunitinib treatment in advanced renal
cell carcinoma patients: a single cancer center experience in
Korea. Cancer Res Treat. 2009;41:67-72.
7. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ,
Miller WH Jr, et al. Safety and efficacy results of the advanced
renal cell carcinoma sorafenib expanded access program in
North America. Cancer. 2010;116:1272-80.
8. Stadler WM, Figlin RA, Ernstoff MS, Curti B, Pendergrass K,
Srinivas S, et al. The Advanced Renal Cell Carcinoma Sora-
fenib (ARCCS) expanded access trial: safety and efficacy in 
patients (pts) with non-clear cell (NCC) renal cell carcinoma
(RCC). J Clin Oncol. 2007;25(18 Suppl):5036.
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor
A, et al. Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med. 2007;356:2271-81.
10. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit
A, Thiele A, et al. Effect of temsirolimus versus interferon-
alpha on outcome of patients with advanced renal cell carci-
noma of different tumor histologies. Med Oncol. 2009;26:202-
9.
11. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin
SF, et al. Everolimus versus sunitinib prospective evaluation
in metastatic non-clear cell renal cell carcinoma (ESPN): a ran-
domized multicenter phase 2 trial. Eur Urol. 2016;69:866-74.
12. Armstrong AJ, Broderick S, Eisen T, Stadler WM, Jones RJ,
Garcia JA, et al. Final clinical results of a randomized phase II
international trial of everolimus vs. sunitinib in patients with
metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin
Oncol. 2015;33(15 Suppl):4507.
13. Hay N, Sonenberg N. Upstream and downstream of mTOR.
Genes Dev. 2004;18:1926-45.
14. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M,
Cognetti F, Zupi G, et al. Antiangiogenic potential of the Mam-
malian target of rapamycin inhibitor temsirolimus. Cancer
Res. 2006;66:5549-54.
15. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology,
prognosis, and targeted therapy for renal cell carcinoma: 
exploiting the hypoxia-induced pathway. Clin Cancer Res.
2003;9:4641-52.
16. Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zus-
tovich F, et al. First-Line Pazopanib in NOn-clear-cell Renal
cArcinoMA: The Italian Retrospective Multicenter PANO-
RAMA Study. Clin Genitourin Cancer. 2017;15:e609-14.
17. Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, et al. Pazo-
panib for the treatment of non-clear cell renal cell carcinoma:
a single-arm, open-label, multicenter, phase II study. Cancer
Res Treat 2018;50:488-94.
18. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD,
Hahn O, et al. Cabozantinib versus sunitinib as initial therapy
for metastatic renal cell carcinoma of intermediate or poor risk
(Alliance A031203 CABOSUN randomised trial): progression-
free survival by independent review and overall survival 
update. Eur J Cancer. 2018;94:115-25.
References
1588 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2019;51(4):1578-1588
